Market Cap | 179.57M | P/E | - | EPS this Y | 30.20% | Ern Qtrly Grth | - |
Income | -132.49M | Forward P/E | -1.24 | EPS next Y | -3.80% | 50D Avg Chg | 8.00% |
Sales | 20.76M | PEG | -0.16 | EPS past 5Y | - | 200D Avg Chg | -33.00% |
Dividend | N/A | Price/Book | 0.68 | EPS next 5Y | 22.30% | 52W High Chg | -72.00% |
Recommedations | 2.10 | Quick Ratio | 6.21 | Shares Outstanding | 68.60M | 52W Low Chg | 41.00% |
Insider Own | 11.59% | ROA | -21.53% | Shares Float | 52.50M | Beta | 3.19 |
Inst Own | 76.16% | ROE | -49.50% | Shares Shorted/Prior | 9.56M/5.29M | Price | 3.66 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,284,451 | Target Price | 18.50 |
Oper. Margin | -1,147.72% | Earnings Date | May 2 | Volume | 404,974 | Change | -1.35% |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Morgan Stanley | Equal-Weight | Feb 26, 24 |
Stifel | Buy | Feb 23, 24 |
JP Morgan | Neutral | Jan 29, 24 |
Stifel | Buy | Dec 13, 23 |
Morgan Stanley | Equal-Weight | Nov 6, 23 |
BMO Capital | Outperform | Nov 3, 23 |
HC Wainwright & Co. | Buy | Nov 2, 23 |
B of A Securities | Neutral | Oct 9, 23 |
HC Wainwright & Co. | Buy | Aug 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Anderson Kenneth Carl | Director Director | Jul 15 | Option | 3.55 | 1,424 | 5,055 | 90,986 | 07/18/22 |
Fisher Stewart | Chief Scientific Off.. Chief Scientific Officer | Apr 12 | Option | 4.35 | 28,084 | 122,165 | 71,390 | 04/12/22 |
Hirsch Andrew | President & CEO President & CEO | Apr 12 | Buy | 8.40 | 10,000 | 84,000 | 10,000 | 04/12/22 |
Anderson Kenneth Carl | Director Director | Jan 26 | Option | 3.55 | 2,137 | 7,586 | 87,975 | 01/26/22 |